ASP Isotopes Inc. (ASPI) Form 10-Q — Nov 16, 2026
ASP Isotopes filed its Q3 2026 10-Q showing revenue of $5.1 million for the quarter, up roughly 4x from $1.3 million a year ago, driven by the January 2026 acquisition of Renergen and growth in its specialist isotopes segment. Nine-month revenue reached $14.4 million versus $3.6 million in the prior-year period. The company still posted a Q3 net loss of $30.9 million (nine-month net loss of $72.0 million), with operating cash burn accelerating to $66.4 million for the nine months as it integrates Renergen and develops its nuclear fuels and helium/LNG segments.
Key figures
- Revenue
- 14427000
- Total Debt
- Convertible notes payable at fair value of $85.9M, current debt $47.7M, noncurrent debt $5.3M
- Revenue Yoy
- +304% (nine months: $14.4M vs $3.6M)
- Total Assets
- 538129000
- Cash Position
- 201663000
- Shares Outstanding
- 155834430
- Q3 2025 revenue
- 1271000
- Q3 2026 revenue
- 5124000
- Share count yoy growth
- 111.7M to 155.8M shares outstanding since Dec 31, 2025
- Gain on convertible note extinguishment
- 11250000
AI analysis
Red flags5 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.